%A Wang,Jia %A Fang,Zhong %A Song,Chao %A Kang,Honglei %A Guo,Qian %A Dong,Yimin %A Zhang,Ya %A Peng,Renpeng %A Guan,Hanfeng %A Li,Feng %D 2020 %J Frontiers in Pharmacology %C %F %G English %K Schisandrin B,osteoclast,Osteoporosis,MAPK,NF-κB,Nrf2 %Q %R 10.3389/fphar.2020.01175 %W %L %M %P %7 %8 2020-July-31 %9 Original Research %+ Hanfeng Guan,Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,China,hguan@hust.edu.cn %+ Feng Li,Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,China,hguan@hust.edu.cn %# %! Schisandrin B inhibits osteoclastogenesis %* %< %T Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss %U https://www.frontiersin.org/articles/10.3389/fphar.2020.01175 %V 11 %0 JOURNAL ARTICLE %@ 1663-9812 %X Osteoporosis is a systemic skeletal disease which is highly prevalent worldwide and considered to be associated with excessive bone resorption mediated by osteoclast. Osteoclast differentiation is featured by the activation of inflammation-related pathways and the generation of reactive oxygen species. Schisandrin B is a bioactive compound with strong antiinflammation and antioxidative properties, we thus speculated that Schisandrin B might serve as a potential candidate for osteoporosis. In the present study, we found that the formation and` function of osteoclasts were dramatically suppressed by Schisandrin B. And consistent with the in vitro results, treatment with Schisandrin B attenuated ovariectomy-induced bone loss in mice. Moreover, Schisandrin B notably inhibited the activation of mitogen activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) pathways and scavenged ROS by activating nuclear factor E2 p45-related factor 2 (Nrf2) signaling. In conclusion, our study indicates that Schisandrin B is an effective approach to treat osteoporosis and other osteoclast-related diseases.